Latest Reimbursement News

Telix Pharmaceuticals has met its upgraded FY 2025 revenue guidance with US$804 million, driven by strong growth in its Precision Medicine segment and the successful US launch of Gozellix. The company also advanced multiple clinical trials and announced a strategic collaboration with Varian to combine radiopharmaceuticals with radiation therapy.

EcoGraf’s maiden exploration in Tanzania delivers promising high-grade gold results, including a standout 4.45 g/t sample at Hazina, while a strategic farm-in with AngloGold Ashanti begins on the Golden Eagle project.

Telix Pharmaceuticals has achieved a key milestone with China’s NMPA accepting its New Drug Application for Illuccix, a prostate cancer imaging agent backed by strong Phase 3 data. This paves the way for Telix to enter a rapidly growing Chinese market alongside its global approvals.

Pacific Edge reports a 13.4% decline in test volumes for Q3 2026 but gains strategic momentum with a key Medicare advisory meeting and clinical endorsements poised to influence reimbursement policy.

Phoslock Environmental Technologies has amended its December 2025 quarterly report to correct funding data and withdraw its sales outlook, while reporting improved cash flow and resuming factory operations.

Mesoblast has received encouraging feedback from the FDA on its cell therapy rexlemestrocel-L, showing meaningful pain relief and potential opioid use reduction in chronic low back pain patients. The company’s ongoing Phase 3 trial aims to confirm these benefits and advance regulatory approval.

Phoslock Environmental Technologies has reversed its cashflow deficits with a quarterly surplus, resumed factory operations after a long pause, and is gearing up for significant sales growth in 2026.

EBR Systems reported a doubling of WiSE System implants in Q4 FY2025 alongside the launch of key clinical studies and preliminary revenue guidance, signalling strong commercial and clinical momentum.

Everest Metals Corporation has officially commenced mining operations at its Mt Dimer Taipan Gold Project in Western Australia, backed by a fully funded agreement with MEGA Resources. Ore extraction is underway with processing set to begin in March 2026, positioning the company for near-term cash flow.

UC San Diego Health has begun clinical use of 4DMedical’s CT – VQ™, marking the fourth leading US academic medical centre to adopt this innovative lung imaging technology since FDA clearance. This milestone underscores 4DMedical’s rapid commercial traction and growing influence in respiratory diagnostics.

Adherium Limited has exceeded its 2025 shipment goals by delivering over 4,600 Hailie® Smartinhaler® devices, including more than 2,000 to Remote Patient Monitoring patients, signaling robust operational momentum.

Artrya Limited has signed a significant five-year commercial agreement with Cone Health, marking its third U.S. customer and solidifying its foothold in the American healthcare market with its AI-powered Salix platform.